<DOC>
	<DOC>NCT00604565</DOC>
	<brief_summary>In maintenance hemodialysis patients, regular administration of parenteral iron by addition of soluble ferric pyrophosphate (SFP) to the dialysate, when compared to conventional dialysate, is effective in preventing the development of iron deficiency, thereby maintaining hemoglobin level; is clinically safe and does not lead to oxidative stress or inflammation.</brief_summary>
	<brief_title>Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Dialysis Solutions</mesh_term>
	<mesh_term>Iron</mesh_term>
	<criteria>Subjects with end stage renal disease undergoing maintenance hemodialysis three times a week. Subjects who have required IV iron at any time in the 2 months preceding enrollment. Subjects with absolute iron deficiency at the time of enrollment In hemodialysis subjects "absolute iron deficiency" Subjects with a current malignancy involving sites other than skin. Subjects with a history of drug or alcohol abuse within the last 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Hemodialysis</keyword>
</DOC>